Drug Profile
Research programme: hepatitis C virus protease and polymerase inhibitors - Novartis/Medivir
Latest Information Update: 05 Jun 2007
Price :
$50
*
At a glance
- Originator Medivir AB
- Developer Medivir AB; Novartis
- Class
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
- 22 Jul 2004 This programme is still in active development
- 07 Sep 2001 Preclinical development for Hepatitis C in Sweden (unspecified route)